FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.
Page 11 of 34
Jun 29, 2026STAT’s recent investigation uncovers key details about Nutex Health’s use of the No Surprises Act to engineer a dramatic financial turnaround. This analysis explores regulatory nuances, Nutex’s evolving business model, and the wider implications for America’s micro hospital and emergency room landscape.
Dr. Alex Morgan
Jun 29, 2026As debate swirls around the structure and reach of the 988 suicide prevention lifeline, LGBTQ+ services stand at a crossroads. Stakeholders weigh concerns, policy shifts, and the critical importance of tailored support for some of the most vulnerable populations in the U.S.
Jonathan Blake
Jun 29, 2026Viridian’s newly approved therapy Lumvoa offers an alternative to Amgen’s market-dominating Tepezza for thyroid eye disease, potentially reshaping patient access and competitive dynamics in this specialty area. The FDA’s decision could have broader implications for pricing, market share, and innovation in rare autoimmune disorders.
Michael Torres
Jun 28, 2026The Medicare Cost Cap Act, introduced with bipartisan national interest, seeks to set a $5,000 limit on annual out-of-pocket expenses for traditional Medicare beneficiaries. This initiative marks a significant policy movement impacting retirees, care providers, insurers, and the broader healthcare economy.
Daniel Cho
Jun 27, 2026The European Commission’s investigation into Sanofi’s alleged antitrust violations marks a significant development in maintaining fair competition across the continent’s pharmaceutical sector. At stake are key principles of fair market behavior and accurate scientific communication, set against the backdrop of public health priorities and evolving regulatory oversight.
Michael Torres
Jun 27, 2026As medetomidine-laced opioids circulate among incarcerated populations, correctional facilities are being forced into a new role as first responders for a uniquely severe withdrawal syndrome. The complexity of the issue—from the pharmacology of medetomidine to resource gaps in prisons—poses new challenges for public health, addiction medicine, and criminal justice policy. We analyze the evolving situation, the gaps in care, and where systemic responses may fall short or present hope.
Dr. Priya Nandakumar
Jun 27, 2026The EMA’s recent stance against Tavneos marks a pivotal development for Amgen and CSL Vifor, as scrutiny over drug safety and market authorization intensifies. As the FDA contemplates a similar move in the United States, the biopharmaceutical landscape braces for regulatory ripple effects that extend well beyond a single product withdrawal.
Jonathan Blake
Jun 26, 2026Across the United States, hundreds of hospitals appear open on paper, but a closer look reveals they have trimmed essential offerings such as emergency care, obstetrics, and psychiatric services. This phenomenon underscores the inadequacy of using closure numbers alone to assess the declining state of healthcare access, especially in rural and underserved areas.
Daniel Cho
Jun 26, 2026A new ACIP charter broadens membership criteria and reduces the committee’s responsibility to recommend new vaccines. This substantial policy shift could signal a reframing of U.S. vaccine advisory processes, with implications for expert composition and the CDC’s broader public health strategy.
Emily Carter
Jun 25, 2026The Supreme Court's latest decision on Roundup litigation represents a pivotal legal event with broad implications for both product liability law and public health governance in the United States. This in-depth analysis explores the legal, scientific, and regulatory factors underpinning the Court’s opinion, assessing what it means for consumers, companies, and the courts going forward.
Daniel Cho
Jun 25, 2026Under President Trump, moves to consolidate scientific leadership and oversight within the CDC have sparked renewed debate over the agency’s independence from political influence. This article explores who stands to gain or lose from the restructuring, the context of CDC’s evolving role, and broader implications for the credibility of federal health agencies.
Dr. Alex Morgan
Jun 25, 2026The FDA has granted Trodelvy, an antibody-drug conjugate from Gilead Sciences, a significant label expansion as a first-line therapy for triple-negative breast cancer (TNBC). This regulatory milestone puts Gilead on closer footing against competitors AstraZeneca and Daiichi Sankyo, intensifying the commercial and scientific race in the ADC space for breast cancer.
Daniel ChoMachine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.